Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:06:51 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:APTO - APTOSE BIOSCIENCES INC - http://aptose.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APTO - Q0.11.20·1.600.11.27+0.010.834.2331841.25  1.29  1.258.6957  1.2019:27:54Mar 2615 min RT 2¢

Recent Trades - Last 10 of 184
Time ETExPriceChangeVolume
19:27:54Q1.26 1
19:27:54Q1.21-0.052
18:46:35Q1.300.045
17:11:18Q1.29940.039437
16:00:01Q1.270.0132
16:00:01Q1.270.014
16:00:01Q1.270.01100
15:59:46Q1.2650.005600
15:59:46Q1.2650.005100
15:59:46Q1.2650.005100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-26 16:01U:APTONews ReleaseAptose Reports Results for the Fourth Quarter and Full Year 2023
2024-03-18 16:30U:APTONews ReleaseAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
2024-01-31 16:01U:APTONews ReleaseAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
2024-01-26 08:00U:APTONews ReleaseAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
2023-12-09 18:30U:APTONews ReleaseAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
2023-11-30 17:00U:APTONews ReleaseAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
2023-11-09 16:00U:APTONews ReleaseAptose Reports Results for the Third Quarter 2023
2023-11-02 09:00U:APTONews ReleaseAptose Tuspetinib Clinical Data Selected for Oral Presentation ‚  at the 2023 ASH Annual Meeting
2023-10-30 09:15U:APTONews ReleaseAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
2023-10-26 07:11U:APTONews ReleaseAptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
2023-10-23 07:30U:APTONews ReleaseAptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
2023-10-16 07:30U:APTONews ReleaseAptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
2023-09-18 07:45U:APTONews ReleaseAptose to Present at the Cantor Global Healthcare Conference
2023-09-06 07:45U:APTONews ReleaseAptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
2023-08-24 07:30U:APTONews ReleaseAptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-10 16:02U:APTONews ReleaseAptose Reports Results for the Second Quarter 2023
2023-07-27 16:04U:APTONews ReleaseAptose to Report Second Quarter 2023 Financial Results and ‚  Hold Conference Call on Thursday, August 10, 2023
2023-06-26 16:05U:APTONews ReleaseAptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
2023-06-10 12:00U:APTONews ReleaseAptose Presents Highlights from Clinical Update
2023-06-05 07:30U:APTONews ReleaseAptose Biosciences Provides Update on Reverse Stock Split